Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV–HCV co-infected patients
| Autor: | Louis Bernard, P. de Truchis, C. Onody, P. Matsiota-Bernard, C. Peronne, Georgia Vrioni |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Microbiology (medical)
Hepatitis C virus Hepacivirus HIV Infections Indinavir Virus Replication medicine.disease_cause Virus Antiretroviral Therapy Highly Active medicine Humans HIV Protease Inhibitor Pharmacology (medical) Viremia Ritonavir biology HIV virus diseases HIV Protease Inhibitors General Medicine Hepatitis C Viral Load medicine.disease biology.organism_classification Virology digestive system diseases CD4 Lymphocyte Count Infectious Diseases Immunology RNA Viral Reverse Transcriptase Inhibitors Viral disease Viral hepatitis Viral load |
| Zdroj: | International Journal of Antimicrobial Agents. 17:155-157 |
| ISSN: | 0924-8579 |
| DOI: | 10.1016/s0924-8579(00)00331-9 |
| Popis: | Ten severely immunocompromised HIV–HCV co-infected patients were enrolled in a quantifiable HCV-RNA assay. Serum alanine aminotransferase, HCV-RNA levels and HIV viral loads were determined at baseline, at month three and at month six after initiation of a highly active antiretroviral therapy including an HIV protease inhibitor. HCV genotypes were determined using a line probe assay kit. Our results suggested that this therapy did not result in lower HCV viraemia, whatever the HCV genotypes, and probably had no effect on the outcome of chronic viral hepatitis C. As our patients were severely immunocompromised and their mean increase of CD4 cell counts was less than 50/mm 3 , we cannot reach any conclusions about the impact of the improvement of immune status on the HCV-RNA load. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect